KRas mutationsare commonly observed in pancreatic ductal adenocarcinoma (PDAC),colorectal cancer (CLC), and nonsmall cell lung cancer (NSCLC)., Specifically, PDAC features >90% KRas mutation and PDAC patientssuffer from near 80% mortality rates., Excellentreviews have discussed KRas’ role as a oncogenic driver., This evidence concerns the gene KRAS and non-small cell lung carcinoma.